SiRNA-mediated IGF-1R inhibition sensitizes human colon cancer SW480 cells to radiation

Acta Oncologica

Volumn 49, Issue 1, 2010, Pages 70-75

  Yavari, Kamal ^a,b   Taghikhani, Mohammad ^a   Maragheh, Mohammad Ghannadi ^b   Mesbah Namin, Seyed A ^a   Babaei, Mohammad Hosein ^b   Arfaee, Ali Jabbary ^c   Madani, Hossein ^c   Mirzaei, Hamid Reza ^c  

^a TARBIAT MODARES UNIVERSITY   (Iran)

^b Nuclear Sciences and Technology Research Institute   (Iran)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; MESSENGER RNA; SMALL INTERFERING RNA; SOMATOMEDIN C RECEPTOR;

ARTICLE; COLON CANCER; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPRESSION VECTOR; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIATION RESPONSE; RADIOSENSITIZATION; RECEPTOR DOWN REGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

CELL LINE, TUMOR; COLONIC NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; RECEPTOR, IGF TYPE 1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 76649101087     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/02841860903334429     Document Type: Article

References (41)

1. Cohen SJ, Cohen, RB, Meropol NJ. Targeting signal transduction pathways in colorectal cancer--more than skin deep. J Clin Oncol 2005;23:5374-85.
2. Labianca R, Beretta G, Gatta G, Braud F, Wils J. Colon cancer. Crit Rev Oncol Hematol 2004;51:145-70.
3. Ansari R, Mahdavinia M, Sadjadi A, Nouraie M, Kamangar F, Bishehsari F, et al. Incidence and age distribution of colorectal cancer in Iran. Results of a population-based cancer registry. Cancer Lett 2006;240:143-7.
4. Sengupta N, Gill KA, Macfi e TS, Lai CS, Suraweera N, McDonald S, Silver A. Management of colorectal cancer: A role for genetics in prevention and treatment. Pathol Res Prac 2008;204:469-77.
5. Luebeck EG, Moolgavkar SH. Multistage carcinogenesis and the incidence of colorectal cancer. Proc Natl Acad Sci USA 2002;99:15095-100.
6. Waters C. Colorectal cancer: An overview. Pharmaceut J 2006;276:323-6.
7. Priebe MG, Vonk RJ, Sun X, He T, Harmsen HJM, Welling GW. The physiology of colonic metabolism possibilities for interventions with pre- and probiotics. Eur J Nutr 2002;41:I2-I10.
8. Krueger H, McLean D, Williams D. Gastrointestinal cancers. Prog Exp Tumor Res 2008;40:85-91.
9. Chung-Faye GA, Kerr DJ. Innovative treatment for colon cancer. BMJ 2000;321:1397-9.
10. Xu R, Zhou B, Fung PC, Li X. Recent advances in the treatment of colon cancer. Histol Histopathol 2006;21:867-72.
11. Chawla AK, Kachnic LK, Clark JW, Willett CG. Combined modality therapy for rectal and colon cancer. Semin Oncol 2003;30:101-12.
12. Giovan GG, Luca S, Michele M. New dimensions in cancer biology and therapy. J Cell Physiol 2000;183:284-7.
13. Voort van Zijp JVD, Hoekstra HJ, Basson MDZ. Evolving management of colorectal cancer. WJG 2008;14:3956-67.
14. Macarulla T, Ramos FJ, Capdevila J, Saura C, Tabernero J. Novel targets for anticancer treatment development in colorectal cancer. Clin Colorectal Cancer 2006;6:265-72.
15. Stassen T, Port M, Nuyken I, Abend M. Radiation-induced gene expression in MCF-7 cells. Int J Radiat Biol 2003;79:319-31.
16. Yin E, Nelson DO, Coleman MA, Peterson LE, Wyrobek AJ. Gene expression changes in mouse brain after exposure to low-dose ionizing radiation. Int J Radiat Biol 2003;79:759-75.
17. Paul D, Adly Y, Joseph C, Ruben C, George A, Kristoffer V, et al. Stress and radiation induced activation of multiple intracellular signalling pathways. Radiat Res 2003;159:283-300.
18. Schmidt-Ullrich RK, Dent P, Grant S, Mikkelsen RB, Valerie K. Signal transduction and cellular radiation responses. Radiat Res 2000;153:245-57.
19. Kuhn C, Hurwitz SA, Kumar MG, Cotton J, Spandau DF. Activation of the insulin-like growth factor-1 receptor promotes the survival of human keratinocytes following ultraviolet B irradiation. Int J Cancer 1999;80:431-8.
20. Yu D, Shibuya H, Miura M. Roles of the insulin like growth factor 1 receptor C-terminus on cellular radioresistance. Biochem Biophys Res Commun 2003;311:174-8.
21. Heron-Milhavet L, LeRoith D. Insulin-like growth factor I induces MDM2-dependent degradation of p53 via the p38 MAPK pathway in response to DNA damage. J Biol Chem 2002;277:15600-6.
22. Ma BBY, Bristow RG, Kim J, Siu LL. Combined-modality treatment of solid tumors using radiotherapy and molecular targeted agents. J Clin Oncol 2003;21:2760-76.
23. Samani AA, Yakar S, LeRoith D, Brodt P. The role of the IGF system in cancer growth and metastasis: Overview and recent insights. Endocr Rev 2007;28:20-47.
24. Freier S, Weiss O, Eran M, Flyvbjerg A, Dahan R, Nephesh I, et al. Expression of the insulin-like growth factors and their receptors in adenocarcinoma of the colon. Gut 1999; 44:704-8.
25. Matthias WM, Christian F, Bin LS, Christina JM, Dieter E, Gustavo B, et al. Overexpression of the insulin-like growth factor I receptor in human colon carcinomas. Cancer 2002; 95:2086-95.
26. Guo YS, Jin GF, Houston CW, Thompson JC, Townsend Jr. CM. Insulin-like growth factor-I promotes multidrug resistance in MCLM colon cancer cells. J Cell Physiol 1998;175:141-8.
27. Pfeffer S, Meister G, Landthaler M, Tuschl T. RNA silencing. B.I.F. FUTURA 2005;20:83-90.
28. Downward J. RNA interference. Br Med J 2004;328:1245-8.
29. Barik S. Silence of the transcripts: RNA interference in medicine. J Mol Med 2005;83:764-73.
30. Grünweller A, Wyszko E, Bieber B, Jahnel R, Erdmann VA, Kurreck J. Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 20-O-methyl RNA, phosphorothioates and small interfering RNA. Nucl Acids Res 2003;31:3185-93.
31. Mittal V. Improving the efficiency of RNA interference in mammals. Nat Rev Genet 2004;5:355-65.
32. Sengupta N, Gill KA, MacFie TS, Lai CS, Suraweera N, McDonald S, Silver A. Management of colorectal cancer: A role for genetics in prevention and treatment. Pathol Res Prac 2008;204:469-77.
33. Cross D, Burmester JK. Gene therapy for cancer treatment: Past, present and future. Clin Med Res 2006;4:218-27.
34. Guerreiro AS, Boller D, Doepfner K T. IGF-IR: potential role in antitumor agents. Drug News Pers 2006;19:261-72.
35. Casa AJ, Dearth RK, Litzenburger BC, Lee AV, Cui X. The type I insulin-like growth factor receptor pathway: A key player in cancer therapeutic resistance. Front Biosci 2008;1:3273-87.
36. Nakanishi Y, Mulshine JL, Kasprzyk PG, Natale RB, Maneckjee R, Avis I, et al. Insulin-like growth factor-I can mediate autocrine proliferation of human small cell lung cancer cell lines in vitro. J Clin Invest 1988;82:354-9.
37. Lee CT, Wu S, Gabrilovich D, Chen H, Nadaf-Rahrov S, Ciernik IF, et al. Antitumor effects of an adenovirus expressing antisense insulin-like growth factor I receptor on human lung cancer cell lines. Cancer Res 1996;56:3038-41.
38. Chernicky CL, Yi L, Tan H, Gan SU, Ilan J. Treatment of human breast cancer cells with antisense RNA to the type I insulin-like growth factor receptor inhibits cell growth, suppresses tumorigenesis, alters the metastatic potential, and prolongs survival in vivo. Cancer Gene Ther 2000;7:384-95.
39. Tan FL, Yin JQ. RNAi, a new therapeutic strategy against viral infection. Cell Res 2004;14:460-6.
40. Collis SJ, Swartz MJ, Nelson WG, DeWeese TL. Enhanced radiation and chemotherapy-mediated cell killing of human cancer cells by small inhibitory RNA silencing of DNA repair factors. Cancer Res 2003;63:1550-4.
41. Rochester MA, Riedemann J, Hellawell GO, Brewster SF, Macaulay VM. Silencing of the IGF1R gene enhances sensitivity to DNA-damaging agents in both PTEN wild-type and mutant human prostate cancer. Cancer Gene Ther 2005; 12(1):90-100.